Register for our free email digests:
Latest From Tiziana Life Sciences PLC
Having become embroiled in a legal tussle with Roche last week concerning the latter's emicizumab, Shire has licensed a hemophilia A bispecific monoclonal antibody of its own.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
This week's roundup includes CEO appointments by Tiziana and Ergomed and executive appointments by Crescendo Biologics, Ablynx, Alexion and Axcella. In addition to this, Oxford BioTherapeutics and Kymab have announced board appointments.
This week’s round-up includes the appointment of independent directors by Sanofi’s board of directors, CEO appointments by Fosun Kite Biotechnology and Milestone Pharmaceuticals as well as executive appointments by Tocagen, GW Pharmaceuticals, Bone Therapeutics and Tris Pharma.
- Therapeutic Areas
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- OxThera AB
- Senior Management
Elisabeth Lindner, CEO
Albert G Fosmoe, II, COO
Harmeet Sidhu, CSO
- Contact Info
Phone: (46) 8 660 02 23
Uppsala, SE-753 20
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.